Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates
1. In concurrent randomized controlled trials (GEMINI 1 and GEMINI 2) of patients with relapsing multiple sclerosis (RMS), tolebrutinib did ...
1. In concurrent randomized controlled trials (GEMINI 1 and GEMINI 2) of patients with relapsing multiple sclerosis (RMS), tolebrutinib did ...
1. In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral tolebrutinib reduced the risk ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Multiple sclerosis patients can sustain axonal injury up to 9 years before symptom onset. 2. Until symptom onset, physical ...
1. Serum neurofilament light chain (sNfL) elevations are a relatively specific biomarker of magnetic resonance imaging (MRI) disease activity in ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. In this randomized controlled trial, multiple sclerosis patients who received frexalimab had fewer new gadolinium-enhancing T1 lesions compared to ...
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.